Management of Portal Hypertension in Cirrhosis with Beta-Blockers

Introduction to Beta-Blocker Therapy

The American Association for the Study of Liver Diseases recommends carvedilol as the preferred non-selective beta-blocker for managing portal hypertension in patients with cirrhosis, with a target dose of 12.5 mg/day 1, 2

Carvedilol has a dual mechanism of action, providing non-selective beta-blockade and mild alpha-1 adrenergic blockade, which reduces both splanchnic blood flow and intrahepatic resistance 1
This dual action results in superior portal pressure reduction compared to propranolol, achieving hemodynamic response in 50-75% of patients versus 46% with traditional NSBBs 3

Carvedilol demonstrated lower rates of first variceal bleeding compared to endoscopic variceal ligation (10% vs. 23%, p=0.04) 1
It significantly reduces progression from small to large varices (20.6% vs. 38.6% with placebo, p=0.04) 4, 1, 2

Initial dose of carvedilol: 6.25 mg once daily, with a target dose of 12.5 mg/day maximum 1, 2
Maintain systolic blood pressure ≥90 mmHg at all times 1, 2

Absolute contraindications during acute bleeding: temporarily suspend all beta-blockers if systolic BP <90 mmHg or MAP <65 mmHg 1, 3
Use with extreme caution in refractory ascites with systolic BP <90 mmHg, serum sodium <130 mEq/L, hepatorenal syndrome, and severe circulatory dysfunction 1, 2

Do NOT use NSBBs to prevent variceal formation in patients without varices—this increases adverse events without benefit 4, 1
Do NOT continue beta-blockers during acute hypotensive bleeding—temporarily suspend until hemodynamic stability is restored 1
Do NOT use excessive doses in patients with ascites—this worsens outcomes 2
Do NOT stop beta-blockers once started (except for contraindications)—bleeding risk recurs when stopped, requiring lifelong therapy 2